Vaccine Development for Epstein-Barr Virus.
Vaccine Development for Epstein-Barr Virus.
复制标题
DOI：
10.1007/978-981-10-7230-7_22
复制
发表时间：
2018
影响因子：
--
通讯作者：
Cohen JI
中科院分区：
文献类型：
--
作者：
Cohen JI
EB病毒(Epstein-Barr Virus，EBV)是传染性单核细胞增多症的主要病因，与多种恶性肿瘤有关，包括鼻咽癌、胃癌、霍奇金淋巴瘤、Burkitt淋巴瘤、免疫功能低下者的淋巴瘤以及多发性硬化症。目前还没有疫苗可用。虽然单体EBV gp350在2期试验中被证明可以降低传染性单核细胞增多症的发生率，但不能降低EBV感染率，但包括多聚体、病毒样颗粒和纳米颗粒在内的较新配方的gp350可能更有效。还包括额外的病毒糖蛋白、裂解蛋白或潜伏蛋白的疫苗也可能提高EBV gp350疫苗的效力。应该进行临床试验，以确定EBV疫苗是否可以降低传染性单核细胞增多症或移植后淋巴增生性疾病的发生率。前者很重要，因为传染性单核细胞增多症可能与虚弱的疲劳和其他并发症有关，而EBV传染性单核细胞增多症与霍奇金淋巴瘤和多发性硬化症的发生率增加有关。一种减少移植后EBV淋巴增生性疾病的疫苗将是预防EBV相关恶性肿瘤的重要原则证据。EBV疫苗用于降低霍奇金淋巴瘤、多发性硬化症或伯基特淋巴瘤发病率的试验将是困难的，但是可行的。
Epstein-Barr virus (EBV) is the primary cause of infectious mononucleosis and is associated with several malignancies, including nasopharyngeal carcinoma, gastric carcinoma, Hodgkin lymphoma, Burkitt lymphoma, and lymphomas in immunocompromised persons, as well as multiple sclerosis. A vaccine is currently unavailable. While monomeric EBV gp350 was shown in a phase 2 trial to reduce the incidence of infectious mononucleosis, but not the rate of EBV infection, newer formulations of gp350 including multimeric forms, virus-like particles, and nanoparticles may be more effective. Vaccine that also include additional viral glycoproteins, lytic proteins or latency proteins might also improve the effectiveness of an EBV gp350 vaccine. Clinical trials to determine if an EBV vaccine can reduce the rate of infectious mononucleosis or post-transplant lymphoproliferative disease should be performed. The former is important since infectious mononucleosis can be associated with debilitating fatigue as well as other complications, and EBV infectious mononucleosis is associated with increased rates of Hodgkin lymphoma and multiple sclerosis. A vaccine to reduce EBV post-transplant lymphoproliferative disease would be an important proof of principle to prevent an EBV associated malignancy. Trials of an EBV vaccine to reduce the incidence of Hodgkin lymphoma, multiple sclerosis, or Burkitt lymphoma would be difficult, but feasible.
登录
查看更多内容
影响因子：
10.1
作者：
Hartlage AS;Liu T;Patton JT;Garman SL;Zhang X;Kurt H;Lozanski G;Lustberg ME;Caligiuri MA;Baiocchi RA
通讯作者：
Baiocchi RA
影响因子：
3.8
作者：
FINERTY, S;TARLTON, J;MORGAN, AJ
通讯作者：
MORGAN, AJ
影响因子：
64.8
作者：
Crotty, S;Kersh, EN;Ahmed, R
通讯作者：
Ahmed, R
影响因子：
64.8
作者：
EPSTEIN, MA;MORGAN, AJ;KIRKWOOD, JK
通讯作者：
KIRKWOOD, JK
在体内对Epstein-Barr病毒的主要免疫反应期间，抗原特异性CD8+ T细胞的直接可视化。
DOI：
10.1084/jem.187.9.1395
发表时间：
1998-05-04
期刊：
The Journal of experimental medicine
影响因子：
--
作者：
Callan MF;Tan L;Annels N;Ogg GS;Wilson JD;O'Callaghan CA;Steven N;McMichael AJ;Rickinson AB
通讯作者：
Rickinson AB